Effects of Tele Speech Therapy on the Treatment of Stammering in Adults Who Stutter

The aim of the study is to determine the effectiveness of telespeech therapy on the treatment of stammering.

Completed

Looking for future studies?

Key information

Conditions

Stammering Communication Disorders Language Disorders Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Speech Disorders Stuttering

Age range

15 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Muaz Medical Complex

Lahore, Punjab Province, 54000, Pakistan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Both Genders
Adults With stuttering 15 to 40 years according to WHO criteria

Exclusion criteria

Stammering with any comorbid are excluded eg. Visual and Hearing Impairment

Treatment and study plan

teletherapy

Other

A teletherapy patient presenting with stammering (stuttering) is a person receiving speech therapy remotely, using technology like video conferencing, to address speech fluency difficulties, often including repetitions, prolongations, or blocks in speech.

Traditionally speech therapy

Other

This type of intervention is traditional speech therapy that will be given to stammering adults, to address speech fluency difficulties, often including repetitions, prolongations, or blocks in speech.

Primary outcomes

Stuttering Severity Instrument - Fourth Edition (SSI4)

Time frame: Base line and 6 weeks

The Stuttering Severity Instrument-Fourth Edition (SSI-4) is a norm-referenced assessment used to quantify stuttering severity in children and adults, measuring frequency, duration, physical concomitants, and the naturalness of speech.

The total score measures the overall severity of the individual's stuttering disorder. The examiner adds scores from the frequency, duration, and physical concomitants sections to obtain the severity score and percentile rank. These are calculated using the tables within the record form. These tables also convert scores to a severity equivalent, which ranges from "very mild" to "very severe".

It has a total score range of 0 to 20 for physical concomitants, and 2 to 18 for frequency and duration. The total score for the entire instrument is the sum of these three scores, making the overall range up to 20 + 18 + 18 = 56.

Sponsors and collaborators

Lead sponsor

Riphah International University

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Apr 22, 2025
Registry last updated: Jul 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed